FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912161078> ?p ?o ?g. }

• W2912161078 endingPage "1873" @default.
• W2912161078 startingPage "1873" @default.
• W2912161078 abstract "Abstract Introduction. In the context of chemoimmunotherapy, complete remission (CR) is more common and is associated with improved survival in patients with chronic lymphocytic leukemia (CLL). CR is less frequent in CLL patients treated with ibrutinib, and the prognostic significance of achieving CR with ibrutinib is indeterminate. Methods. We prospectively analyzed 208 CLL patients treated on a phase 2 study (NCT02007044) of first-line (deletion 17p only; n=27) or salvage ibrutinib (n=181), with or without rituximab, between 12/2013 and 01/2018. Response was assessed by international workshop on CLL 2018 guidelines. Categorical variables were compared using the χ2 or Fisher exact tests. Progression-free survival (PFS) was defined as time from treatment initiation to disease progression and/or death, and Kaplan-Meier curves compared using the log-rank test. A landmark analysis at median time of CR achievement (best response) was performed for PFS. Results. After a median follow-up of 34 months (range, 3-48 months), response was evaluable in 194 patients, overall response rate (ORR) was 99%, and CR rate was 24%, with negative minimal residual disease (MRD) in 3% of patients; median time to response was 10 months (range, 3-45 months) and median time to CR was 21 months (5-45 months). None of the patients' baseline characteristics associated with achievement of CR (Table). Among the 47 patients in CR, 7 (15%) discontinued treatment, after a median time from treatment initiation of 19 months (range, 10-39); the main cause of discontinuation was toxicity (5 patients), with second cancer (metastatic melanoma) and disease progression prompting treatment discontinuation only in 2 patients. Among the 145 patients in PR, 50 (34%) discontinued treatment, after a median time from treatment initiation of 14 months (range, 4-45 months); while the main cause of discontinuation was again toxicity (26 patients), 2nd cancers and progressive disease prompted treatment discontinuation in 5 and 14 patients, respectively. Remaining causes of treatment discontinuation among patients in PR were loss to follow-up (3 patients) and consolidation therapy (2 patients). Median PFS was not reached and 28 patients (13%) progressed and/or died. Achievement of CR significantly associated with prolonged PFS (4-year PFS 98% vs 78%, p=0.03)(Figure). The association between CR and prolonged PFS was also confirmed on a landmark analysis (21 months)(p=0.05). Among baseline characteristics shown in the Table, the only factor associated with prolonged PFS was absence of complex karyotype (4-year PFS 80% vs 40%, p=0.05). Median OS has not been reached and 16 (8%) patients have died; of these, only 1 patient was in CR (and cause of death was metastatic melanoma), whereas the remaining 15 were in PR. Among patients in PR, causes of death were: infections in 7 patients, 2nd cancers in 2 patients, Richter transformation in 2 patients and other in 4 patients (small bowel obstruction, colon perforation, intracranial hemorrhage, bradyarrhythmia). Conclusions. This is the first study showing that achievement of CR is a desirable endpoint for patients with CLL treated with ibrutinib, associating with prolonged PFS. Our results support the development of future combination studies, aimed at achieving higher rates of CR in patients treated with ibrutinib. Figure. Figure. Disclosures Wierda: AbbVie, Inc: Research Funding; Genentech: Research Funding. Jain:Infinity: Research Funding; Novimmune: Honoraria, Membership on an entity's Board of Directors or advisory committees; Genentech: Research Funding; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS: Research Funding; Infinity: Research Funding; ADC Therapeutics: Research Funding; Astra Zeneca: Research Funding; Cellectis: Research Funding; Verastem: Research Funding; Servier: Honoraria, Membership on an entity's Board of Directors or advisory committees; Incyte: Research Funding; ADC Therapeutics: Research Funding; BMS: Research Funding; ADC Therapeutics: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Research Funding; Pharmacyclics: Research Funding; Genentech: Research Funding; Abbvie: Research Funding; Celgene: Research Funding; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Adaptive Biotechnologies: Honoraria, Membership on an entity's Board of Directors or advisory committees; Servier: Research Funding; Pharmacyclics: Research Funding; Seattle Genetics: Research Funding; Seattle Genetics: Research Funding; Abbvie: Research Funding; Pfizer: Research Funding; Incyte: Research Funding; Adaptive Biotechnologioes: Research Funding; Celgene: Research Funding; Pharmacyclics: Honoraria, Membership on an entity's Board of Directors or advisory committees; Astra Zeneca: Research Funding; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees; Astra Zeneca: Honoraria, Membership on an entity's Board of Directors or advisory committees; Servier: Research Funding; Verastem: Honoraria, Membership on an entity's Board of Directors or advisory committees; Verastem: Research Funding; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; ADC Therapeutics: Honoraria, Membership on an entity's Board of Directors or advisory committees; Cellectis: Research Funding; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Adaptive Biotechnologioes: Research Funding; Servier: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pharmacyclics: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novimmune: Honoraria, Membership on an entity's Board of Directors or advisory committees; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees; Adaptive Biotechnologies: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Astra Zeneca: Honoraria, Membership on an entity's Board of Directors or advisory committees; Verastem: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees. Thompson:Adaptive Biotechnologies: Research Funding; Genentech: Honoraria, Membership on an entity's Board of Directors or advisory committees; AbbVie: Honoraria, Research Funding; Gilead Sciences: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pharmacyclics: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding." @default.
• W2912161078 created "2019-02-21" @default.
• W2912161078 creator A5000450477 @default.
• W2912161078 creator A5021380291 @default.
• W2912161078 creator A5027575595 @default.
• W2912161078 creator A5028845635 @default.
• W2912161078 creator A5038196228 @default.
• W2912161078 creator A5058755419 @default.
• W2912161078 creator A5080883357 @default.
• W2912161078 creator A5083315699 @default.
• W2912161078 creator A5084290698 @default.
• W2912161078 creator A5089428686 @default.
• W2912161078 creator A5090435894 @default.
• W2912161078 date "2018-11-29" @default.
• W2912161078 modified "2023-10-18" @default.
• W2912161078 title "Association between Quality of Response and Outcome in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib" @default.
• W2912161078 doi "https://doi.org/10.1182/blood-2018-99-111044" @default.
• W2912161078 hasPublicationYear "2018" @default.
• W2912161078 type Work @default.
• W2912161078 sameAs 2912161078 @default.
• W2912161078 citedByCount "0" @default.
• W2912161078 crossrefType "journal-article" @default.
• W2912161078 hasAuthorship W2912161078A5000450477 @default.
• W2912161078 hasAuthorship W2912161078A5021380291 @default.
• W2912161078 hasAuthorship W2912161078A5027575595 @default.
• W2912161078 hasAuthorship W2912161078A5028845635 @default.
• W2912161078 hasAuthorship W2912161078A5038196228 @default.
• W2912161078 hasAuthorship W2912161078A5058755419 @default.
• W2912161078 hasAuthorship W2912161078A5080883357 @default.
• W2912161078 hasAuthorship W2912161078A5083315699 @default.
• W2912161078 hasAuthorship W2912161078A5084290698 @default.
• W2912161078 hasAuthorship W2912161078A5089428686 @default.
• W2912161078 hasAuthorship W2912161078A5090435894 @default.
• W2912161078 hasBestOaLocation W29121610781 @default.
• W2912161078 hasConcept C126322002 @default.
• W2912161078 hasConcept C141071460 @default.
• W2912161078 hasConcept C143998085 @default.
• W2912161078 hasConcept C151730666 @default.
• W2912161078 hasConcept C2776694085 @default.
• W2912161078 hasConcept C2777938653 @default.
• W2912161078 hasConcept C2778461978 @default.
• W2912161078 hasConcept C2778715236 @default.
• W2912161078 hasConcept C2778822529 @default.
• W2912161078 hasConcept C2779343474 @default.
• W2912161078 hasConcept C2779878957 @default.
• W2912161078 hasConcept C2780739268 @default.
• W2912161078 hasConcept C2780790343 @default.
• W2912161078 hasConcept C71924100 @default.
• W2912161078 hasConcept C86803240 @default.
• W2912161078 hasConcept C90924648 @default.
• W2912161078 hasConceptScore W2912161078C126322002 @default.
• W2912161078 hasConceptScore W2912161078C141071460 @default.
• W2912161078 hasConceptScore W2912161078C143998085 @default.
• W2912161078 hasConceptScore W2912161078C151730666 @default.
• W2912161078 hasConceptScore W2912161078C2776694085 @default.
• W2912161078 hasConceptScore W2912161078C2777938653 @default.
• W2912161078 hasConceptScore W2912161078C2778461978 @default.
• W2912161078 hasConceptScore W2912161078C2778715236 @default.
• W2912161078 hasConceptScore W2912161078C2778822529 @default.
• W2912161078 hasConceptScore W2912161078C2779343474 @default.
• W2912161078 hasConceptScore W2912161078C2779878957 @default.
• W2912161078 hasConceptScore W2912161078C2780739268 @default.
• W2912161078 hasConceptScore W2912161078C2780790343 @default.
• W2912161078 hasConceptScore W2912161078C71924100 @default.
• W2912161078 hasConceptScore W2912161078C86803240 @default.
• W2912161078 hasConceptScore W2912161078C90924648 @default.
• W2912161078 hasIssue "Supplement 1" @default.
• W2912161078 hasLocation W29121610781 @default.
• W2912161078 hasOpenAccess W2912161078 @default.
• W2912161078 hasPrimaryLocation W29121610781 @default.
• W2912161078 hasRelatedWork W2267257595 @default.
• W2912161078 hasRelatedWork W2887407030 @default.
• W2912161078 hasRelatedWork W2902590192 @default.
• W2912161078 hasRelatedWork W2911933749 @default.
• W2912161078 hasRelatedWork W2912161078 @default.
• W2912161078 hasRelatedWork W2988709229 @default.
• W2912161078 hasRelatedWork W3095638461 @default.
• W2912161078 hasRelatedWork W3096833615 @default.
• W2912161078 hasRelatedWork W4206586970 @default.
• W2912161078 hasRelatedWork W4294292858 @default.
• W2912161078 hasVolume "132" @default.
• W2912161078 isParatext "false" @default.
• W2912161078 isRetracted "false" @default.
• W2912161078 magId "2912161078" @default.
• W2912161078 workType "article" @default.